MediWound offers catalyst-rich asymmetric upside, pairing an approved burn-care biologic with a potentially disruptive chronic wound therapy—though execution, trial timing, cash burn, and geopolitical risks remain material.
MediWound Ltd. (MDWD) is a pioneering, fully integrated biopharmaceutical leader focused on the development, manufacture, and global commercialization of next-generation enzymatic therapeutics for non-surgical tissue repair.[1, 2, 3] The company operates primarily within three distinct, high-value clinical segments: acute burn care, chronic wound management, and early-stage dermatology and oncology.[2, 3] Operating from its headquarters in Yavne, Israel, MediWound utilizes a proprietary, highly scalable biotherapeutic platform based on proteolytic enzymes extracted from bromelain.[2, 3, 4] This platform is designed to selectively digest non-viable necrotic tissue (eschar) while completely preserving healthy surrounding cells and the underlying viable dermis, thereby fundamentally shifting the clinical standard of care away from invasive surgical intervention.[3, 5, 6]
+---------------------------------------+
| MediWound Ltd. (MDWD) |
+-------------------+-------------------+
|
+------------------------+------------------------+
| |
+--------v--------+ +--------v--------+
| Burn Care | | Wound Care |
+--------+--------+ +--------+--------+
| |
| Approved (Adult/Peds) | Phase III VALUE Trial
| Exclusively Licensed to Vericel (North America) | Strategic Partnerships (Mölnlycke, etc.)
| |
+--------v--------+ +--------v--------+
| NexoBrid® | | EscharEx® |
+-----------------+ +-----------------+
The company generates revenues through a robust, diversified business model comprising product sales, licensing royalties, milestone payments, and funded government development contracts.[7, 8, 9] Under regional licensing structures, such as its exclusive agreement with Vericel Corporation for North America, MediWound manufactures products on a per-unit transfer price basis and collects tiered royalties ranging from mid-single-digit to mid-teen percentages on net commercial sales.[8, 10] In international markets, the company utilizes regional distributors, including Kaken Pharmaceutical in Japan and Bharat Serums and Vaccines in India.[9] Additionally, MediWound derives substantial non-dilutive development and procurement revenues from long-term contracts with government bodies like the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Department of War.[7, 11]
MediWound’s core products and pipeline consist of:
* NexoBrid® (anacaulase-bcdb): An FDA-, EMA-, and PMDA-approved biological orphan drug indicated for the rapid, non-surgical removal of eschar in deep partial-thickness and full-thickness thermal burns across all age groups, newborn through adult.[1, 5, 6]
* EscharEx®: A late-stage investigational biologic concentrate of proteolytic enzymes enriched with bromelain, currently in a global Phase III trial (VALUE) for the debridement of chronic wounds, specifically venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs).[12, 13]
* MW005: A topically applied biologic in Phase I/II development targeting non-melanoma skin cancers, specifically basal cell carcinoma.[2, 3]
The primary customer segments for MediWound's therapies are highly specialized, concentrated institutional buyers.[7, 14] For NexoBrid, these include the approximately 90 regional burn care centers in the United States, pediatric specialized hospitals, and national emergency preparedness agencies managing strategic military stockpiles.[7, 10, 14] For EscharEx, the primary customer base expands to outpatient wound care clinics, long-term care facilities, and general hospital outpatient departments.[15, 16]
Clinicians and healthcare payors choose MediWound’s therapies over alternative interventions due to their superior clinical efficacy and resource optimization.[6, 13] Traditional debridement relies on surgical excision, which requires scarce operating room resources, exposes patients to general anesthesia, and is inherently non-selective, often removing healthy dermal tissue and leading to severe long-term scarring.[6, 10] In contrast, NexoBrid achieves complete eschar removal within a median of one day (compared to six days under standard surgical care), reduces the necessity of autograft surgery from 64.4% to 8.3%, preserves viable dermis, and improves long-term scar quality.[6, 17]
The primary short-term commercial driver for MediWound is the expansion of NexoBrid's institutional footprint.[7, 10] Vericel’s commercial launch in North America has achieved broad utilization, capturing over 70 of the 90 targeted burn centers in the United States.[7, 10] The market opportunity was expanded by the FDA’s pediatric approval of NexoBrid, allowing the company to target approximately 20 pediatric burn centers in the United States.[10, 17] To meet this anticipated global demand, MediWound constructed and operationalized a new cGMP-compliant sterile manufacturing facility, which increases production capacity sixfold and is expected to receive final regulatory approvals.[7, 11, 14] This scaled production setup is projected to expand gross margins to more than 65% as plant utilization climbs.[15]
A major strategic driver is the ten-year BARDA contract awarded to Vericel, valued at up to $197 million.[18, 19] This long-term contract supports NexoBrid procurement, vendor-managed inventory services, next-generation manufacturing capabilities, and clinical development for potential blast-trauma indications.[18, 19] Initial procurement activities are expected to begin in the second half of 2026, establishing a predictable, high-margin, non-dilutive revenue stream.[20, 21]
MediWound possesses a multi-layered competitive moat that protects its market position:
* Orphan Biologic Status: NexoBrid holds orphan drug designations in the United States, Europe, and Japan, securing seven to ten years of regulatory exclusivity post-approval.[3, 5]
* Technological and Manufacturing Complexity: The extraction and sterile formulation of bioactive proteolytic enzymes from bromelain are technically challenging.[13, 14] Replicating this proprietary process presents significant hurdles for biosimilar developers.[7]
* High Institutional Switching Costs: Integrating enzymatic debridement requires comprehensive institutional clinical training, protocol adjustments, and Pharmacy and Therapeutics (P&T) committee approvals.[9, 10] Once a clinical team adopts NexoBrid, reverting to invasive surgical excision represents a setback in institutional efficiency.[6, 10]
* Strategic Distribution Ecosystem: MediWound has integrated itself into the global wound care ecosystem through research and commercial collaboration agreements with major industry players, including Mölnlycke Health Care, Solventum (formerly 3M Healthcare), B. Braun, Convatec, and MIMEDX.[7, 22] This partnership approach leverages existing distribution networks, mitigating commercial execution risks.[7]
MediWound’s target market opportunity spans two distinct segments, with chronic wound care representing the largest potential driver:
| Product Segment | Geographic Focus | Estimated Target Patient/Clinic Base | Target Addressable Market (TAM) |
|---|---|---|---|
| NexoBrid® (Severe Burns) | United States & Global | Hospitalized patients requiring eschar removal across ~90 burn centers [7, 10, 14] | $300 Million (U.S.) (Assumes NexoBrid average price of ~$9,000 per patient) [14, 15] |
| EscharEx® (Chronic Wounds) | United States & Global | Patients in outpatient wound clinics with VLUs, DFUs, and pressure ulcers [12, 15] | >$2.0 Billion - $2.5 Billion (U.S.) [14, 15] |
EscharEx represents the company’s primary long-term valuation driver.[2] The chronic wound debridement market is currently dominated by a single biologic agent: Smith & Nephew’s SANTYL® (collagenase ointment), which generates annual sales exceeding $360 million to $400 million.[13, 14, 18, 23] Clinically, SANTYL is limited by its slow debridement velocity, often requiring weeks or months of daily applications to prepare the wound bed.[13, 14]
Head-to-head clinical and preclinical data demonstrate that EscharEx achieves complete debridement and wound bed preparation in a median of 11 days, compared to 63 days for standard care and 85 days for gel vehicles.[14] Furthermore, EscharEx disrupts biofilm and reduces bacterial load, addressing key pathologies that delay wound healing.[14]
The competitive landscape is consolidated among a few major medtech players: Smith & Nephew plc, Mölnlycke Health Care AB, ConvaTec Group plc, and Coloplast A/S.[16, 24] Rather than competing directly against these entities in the outpatient setting, MediWound has strategically partnered with them.[7, 22] This positioning allows MediWound to act as an API provider and clinical collaborator, mitigating commercial execution risks while preparing to capture market share from SANTYL.[13, 14, 22]
MediWound reported its first-quarter fiscal 2026 financial results on May 27, 2026.[20]
On the Q1 2026 earnings call, CEO Ofer Gonen noted that while the EscharEx Phase III VALUE trial continues to enroll patients across more than 30 active sites in the U.S., Europe, and Israel, progress has been more gradual than originally anticipated.[18, 25] Consequently, the company implemented targeted recruitment initiatives, adjusting the timeline for the pre-specified interim sample size assessment and overall enrollment completion to the first quarter of 2027.[20, 25] Management remains confident in Vericel’s launch of NexoBrid, particularly as the new 10-year BARDA procurement contract begins contributing in the second half of 2026.[20, 21]
The market reacted negatively to the Q1 revenue miss, with the stock price falling 14.09% on the day of the announcement, closing at $13.86 on heavy volume.[20] This decline reduced the company's market capitalization to approximately $214.38 million at that time.[20] In response, Oppenheimer lowered its price target by $1.00 to $32.00, citing risk from dependence on BARDA revenue timing, but maintained its Outperform rating.[28] H.C. Wainwright maintained its $36.00 price target.[30] Consensus remains a Strong Buy among covering analysts, with price targets ranging from $22.00 to $36.00 and an average 12-month target of $29.00.[31, 32]
Evaluating MediWound requires connecting its clinical pipeline to its long-term financial model:
+-------------------------------------------------------+
| 5-Year Revenue Growth Bridge |
+-------------------------------------------------------+
| 2025 Actual: $16.96M |
| | |
| +--> 2026 Guidance: $24.0M - $26.0M |
| | |
| +--> 2027 Guidance: $32.0M - $35.0M |
| | |
| +--> 2028 Guidance: $50.0M - $55.0M|
| | |
| +--> 2030 Consensus: $168.40M
+-------------------------------------------------------+
Historically, revenues decreased from $23.76 million in 2021 to $16.96 million in 2025, representing a negative compound annual growth rate of approximately 8.1%.[25, 33] This decline is highly deceptive for long-term investors, as it reflects the lumpiness of non-recurring licensing milestone payments, such as the $7.50 million received from Vericel in 2022 upon BLA submission, alongside temporary disruptions like the 2025 U.S. government shutdown that delayed contract renewals.[7, 33]
Looking forward, the company is entering a high-growth phase. Reaffirmed long-term guidance projects revenues of $24 million to $26 million in 2026, $32 million to $35 million in 2027, and $50 million to $55 million in 2028.[7, 11] Consensus analyst estimates project a revenue ramp to $108.70 million in 2029 and $168.40 million by 2030, representing a projected 5-year sales CAGR of approximately 58.2% from the 2025 baseline.[7, 31]
To contextualize MediWound's valuation relative to its industry peers, the following table benchmarks its Enterprise Value-to-Revenue (EV/Revenue) multiple against public biotechnology and wound care companies:
| Company Name | Ticker | Enterprise Value (USD) | LTM Revenue (USD) | EV / Revenue Multiple |
|---|---|---|---|---|
| Vyne Therapeutics Inc | VYNE | N/A | N/A | -11.7x [34] |
| Organogenesis Holdings Inc | ORGO | N/A | N/A | 0.8x [34] |
| Vericel Corp Ord | VCEL | N/A | N/A | 5.4x [34] |
| Redhill Biopharma Ltd | RDHL | N/A | N/A | 7.7x [34] |
| MediWound Ltd | MDWD | $163.40 Million | $16.96 Million | 9.6x [34] |
| Sol-Gel Technologies Ltd | SLGL | N/A | N/A | 10.3x [34] |
While MediWound trades at an EV/Revenue multiple of 9.6x, this valuation is supported by its late-stage pipeline asset, EscharEx, which targets a multi-billion dollar market opportunity, and its low capital intensity model, which leverages partner salesforces.[8, 14, 34]
+---------------------------------------------------------------------------------+
| MDWD Risk Matrix |
+---------------------------------------------------------------------------------+
| |
| * EscharEx VALUE Trial Failure |
| * Loss / Material Downsizing of BARDA Contract |
| * Permanent Regulatory Rejection of cGMP Facility |
| |
| * Delay of EscharEx Assessment Beyond Q1 2027 |
| * Weak NexoBrid Uptake (<$15M) by Vericel |
| * Unplanned Dilutive Capital Raise |
| |
| * Delayed Shipments from Geopolitical Tensions |
| * Elevated Cash Burn Outflow |
| |
+---------------------------------------------------------------------------------+
The primary company-specific risk relates to the clinical development of EscharEx, specifically the global Phase III VALUE trial in venous leg ulcers.[2, 13] Clinical trial enrollment is progressing more gradually than originally anticipated, pushing the expected completion of enrollment and the interim sample size assessment to the first quarter of 2027.[20, 25] Any further delays in patient enrollment would push back the potential biological license application (BLA) submission and subsequent commercial launch, which is currently projected to contribute to revenues by 2028.[7, 11] Additionally, the sixfold scale-up of the expanded manufacturing facility is pending final regulatory approvals.[7, 11] Any regulatory delay would limit commercial supply capabilities and cap NexoBrid's growth potential.[7, 11]
In the acute burn care segment, NexoBrid faces minimal direct biologic competition but must compete against established surgical debridement standards.[6, 10] For EscharEx, the primary competitive threat is Smith & Nephew's SANTYL, which possesses a deeply entrenched clinical footprint and generates annual sales of $360 million to $400+ million.[13, 14, 18] Smith & Nephew may respond to the threat of EscharEx by adjusting its pricing, offering bundled discounts, or expanding its clinical program.[23] Furthermore, consolidation in the wound care sector—such as Solventum’s $725 million acquisition of Acera Surgical and Mölnlycke’s ongoing M&A activities—could strengthen the commercial capability of competing biologic and synthetic debridement platforms.[24]
MediWound is highly reliant on a limited group of partners and government customers.[7, 8, 10] The North American commercialization of NexoBrid is single-source dependent on Vericel.[10] Any operational, regulatory, or financial disruptions at Vericel would directly impact royalty revenues.[8, 10] Furthermore, a significant portion of MediWound's revenue is tied to U.S. government agencies (DoD and BARDA).[7, 11] As seen in fiscal year 2025, where a U.S. government shutdown delayed contract approvals and reduced revenues to $17 million, the timing of these revenues is subject to federal budget appropriations and legislative changes.[7, 11]
MediWound is in a capital-intensive phase of clinical development, incurring significant operating cash outflows ($9.60 million in Q1 2026, $21.40 million in FY2025).[7, 20] While the current cash balance of $44.65 million provides operational runway into 2027, the company remains unprofitable and may require additional capital to fund the commercialization of EscharEx.[2, 25] If the cash burn rate remains elevated or revenues ramp slower than expected, the company may need to pursue dilutive equity offerings, which would dilute existing shareholders.[2, 35]
Headquartered in Yavne, Israel, MediWound is exposed to regional geopolitical instability.[4, 18, 20] This risk was realized in Q1 2026, when regional conflict caused postponed shipments and contributed to the quarterly revenue miss.[18, 20] Prolonged conflict could disrupt supply chains, cause labor shortages, or damage production facilities.[20] Globally, the company is sensitive to inflation-driven manufacturing cost increases and changes in Medicare reimbursement structures, which influence hospital purchasing behavior.[24]
To evaluate MediWound's potential return profile over the next five years (mid-2026 through mid-2031), this analysis models three distinct operational cases. This model assumes a baseline share price of $14.00 USD, 12.85 million outstanding ordinary shares, and no immediate exercise of out-of-the-money warrants.[36, 37, 38]
+------------------------------------+
| Estimated Future Valuation (2031) |
+-----------------+------------------+
|
+------------------------+------------------------+
| | |
+--------v--------+ +--------v--------+ +--------v--------+
| High Case | | Base Case | | Low Case |
| (25% Prob) | | (55% Prob) | | (20% Prob) |
+--------+--------+ +--------+--------+ +--------+--------+
| | |
| $155.70 USD | $69.00 USD | $2.70 USD
| (1,012% Return) | (393% Return) | (-81% Return)
| | |
+------------------------+------------------------+
|
v
+--------------------------+
| Probability-Weighted PT |
| $77.42 USD |
+--------------------------+
The Base Case assumes that NexoBrid achieves steady adoption in the U.S. across the target burn center footprint, and that the 10-year BARDA contract operates smoothly.[10, 18] EscharEx finishes its VALUE trial with positive results, receives FDA approval in late 2028, and launches commercially in 2029.[7, 11, 13]
* Operating Assumptions: Year 5 (2031) revenue reaches $200.00 million USD, representing a 63.7% CAGR from the 2025 actual revenue of $17.00 million USD.[7] Net profit margin reaches 20.0%, driven by higher-margin product royalty mixes and manufacturing efficiencies.[8, 15]
* Financial Bridge: This revenue and margin profile yields $40.00 million USD in net income. Dilution from option exercises and potential minor capital raises increases the outstanding share count to 14.50 million. Implied EPS is $2.76 USD.
* Valuation & Exit: Applying a standard mid-cap biotechnology P/E multiple of 25.0x yields an implied future share price of $69.00 USD.[2]
The High Case assumes that EscharEx achieves rapid market penetration, taking significant market share from Smith & Nephew's SANTYL in the $2.0 billion+ chronic wound market.[13, 14] Vericel fully utilizes the $197 million BARDA contract, and MediWound triggers $15.00 million in non-dilutive commercial milestone payments.[8, 18]
* Operating Assumptions: Year 5 revenue reaches $280.00 million USD, representing a 75.1% CAGR from the 2025 baseline.[7] Net margin expands to 25.0% due to milestone payments and higher manufacturing utilization.[8, 15]
* Financial Bridge: Net income reaches $70.00 million USD. Milestone payments and warrant exercise proceeds limit additional equity dilution, keeping the outstanding share count at 13.50 million. Implied EPS is $5.19 USD.
* Valuation & Exit: An expansion of the P/E multiple to 30.0x, reflecting high growth and dominant market share, yields an implied future share price of $155.70 USD.[2]
The Low Case assumes that EscharEx fails its Phase III VALUE trial, or requires a second clinical trial, postponing FDA approval beyond the 5-year window.[13, 39] NexoBrid remains a niche product with slow adoption, and government procurement remains volatile.[7, 11]
* Operating Assumptions: Year 5 revenue is limited to $60.00 million USD, driven primarily by NexoBrid and government services.[7, 11] Net margin is limited to 5.0% due to ongoing R&D expenses and lower manufacturing utilization.[15, 20]
* Financial Bridge: This profile yields $3.00 million USD in net income. Due to ongoing cash burn, the company is forced to execute dilutive equity financings, increasing the outstanding share count to 17.00 million. Implied EPS is $0.18 USD.
* Valuation & Exit: Applying a compressed P/E multiple of 15.0x yields an implied future share price of $2.70 USD.[2]
| Scenario | Revenue in Year 5 (USD) | Margin / Earnings Assumption | Valuation Multiple Assumption | Current Share Price (USD) | Implied Future Share Price (USD) | 5-Year Total Return | Annualized Return | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | $280.00 Million | 25.0% Net Margin / $5.19 EPS | 30.0x P/E | $14.00 | $155.70 | 1,012.1% | 61.9% | 25% |
| Base Case | $200.00 Million | 20.0% Net Margin / $2.76 EPS | 25.0x P/E | $14.00 | $69.00 | 392.9% | 37.6% | 55% |
| Low Case | $60.00 Million | 5.0% Net Margin / $0.18 EPS | 15.0x P/E | $14.00 | $2.70 | -80.7% | -28.2% | 20% |
| Weighted | $192.00 Million | 18.3% Margin | 24.3x P/E | $14.00 | $77.42 | 453.0% | 40.8% | 100% |
Based on these subjective probability weights, the probability-weighted 5-year target price is estimated at $77.42 USD, representing an annualized return of 40.8%.
ASYMMETRIC GROWTH POTENTIAL
To evaluate the operational quality and fundamental durability of MediWound, the company is rated across ten key dimensions. These scores reflect its late-stage pipeline potential and its near-term financial and geopolitical challenges [2, 13, 20]:
The management team’s incentives are aligned with shareholders.[35] CEO Ofer Gonen directly holds 275,424 ordinary shares, representing a 2.1% ownership stake.[35, 38] Executive compensation includes performance-based equity grants.[40] Furthermore, board members Nachum Shamir and David Morton Fox reported open-market purchases of shares in June 2026, indicating confidence in the company’s valuation.[41, 42]
The transition of NexoBrid to a recurring royalty structure with Vericel and Kaken improves revenue predictability.[8, 9] However, near-term revenues remain lumpy and dependent on the timing of BARDA and DoD contract allocations, as well as geopolitical events.[7, 11, 20]
In burn care, NexoBrid maintains an uncontested biologic position in non-surgical debridement.[1, 10] In the chronic wound care segment, MediWound is positioned as a challenger to SANTYL as EscharEx progresses in clinical trials.[13, 14, 18]
The growth outlook is supported by a 58.2% projected revenue CAGR through 2030, the expansion of NexoBrid into a $300 million pediatric market, and EscharEx's addressable chronic wound care TAM of more than $2.0 billion.[5, 10, 14, 31]
MediWound holds $44.65 million in cash and short-term bank deposits with no debt.[15, 25] However, the current cash burn rate ($9.60 million operating outflow in Q1 2026) limits the company's financial flexibility unless commercial revenues accelerate.[20]
The long-term viability of the business is supported by its cGMP manufacturing facility and strategic collaborations with established healthcare companies like Mölnlycke, Solventum, B. Braun, and Convatec.[7, 11, 22]
Management’s capital allocation strategy focuses on clinical development while utilizing partners' commercial infrastructure.[7, 8] The expansion of cGMP capacity supports future commercial needs.[7, 11]
Wall Street sentiment remains positive, with covering analysts maintaining Outperform or Buy ratings.[31, 43] Despite the Q1 revenue miss, analysts adjusted price targets only slightly, indicating confidence in the underlying pipeline value.[28, 30]
The company is currently unprofitable, with negative operating margins exceeding -180% and a net loss of $3.00 million in Q1 2026.[20, 38] Sustained profitability is not anticipated until the commercial scale-up of EscharEx.[7, 11]
MediWound has a mixed track record of shareholder value creation due to past regulatory delays, historical dilutive equity offerings, and volatile revenue performance.[11, 35, 44]
| Evaluation Dimension | Assigned Score (1-10) | Core Fundamental Driver |
|---|---|---|
| Management Alignment | 8 / 10 | Direct shareholdings by CEO; active insider buying by board members in June 2026 [35, 41, 42] |
| Revenue Quality | 6 / 10 | Predictable royalty structures, but lumpy milestones and government budget dependencies [7, 8, 11] |
| Market Position | 7 / 10 | Unchallenged burn biologic; clinical challenger in chronic wound debridement [1, 13, 14] |
| Growth Outlook | 9 / 10 | Large addressable TAM for EscharEx; pediatric label expansions; high projected CAGR [5, 14, 31] |
| Financial Health | 6 / 10 | Positive net cash position with no debt, offset by near-term operating cash burn [15, 20, 25] |
| Business Viability | 8 / 10 | Global partnerships with major medtech companies; manufacturing capacity [7, 11, 22] |
| Capital Allocation | 7 / 10 | Leveraged commercial structure; capacity expansion, offset by high R&D requirements [7, 8, 11] |
| Analyst Sentiment | 9 / 10 | High institutional conviction; consensus Buy; average PT of $29.00 USD [31, 32] |
| Profitability | 3 / 10 | Elevated operating losses; transition to net profitability dependent on pipeline milestones [7, 20, 31] |
| Track Record | 5 / 10 | History of milestone-dependent revenues, geopolitical disruptions, and share dilution [11, 20, 35] |
| Blended Score | 6.8 / 10 | Pipeline-driven value with near-term execution and geopolitical headwinds |
DISRUPTIVE OPTIONALITY UNLOCKED
MediWound Ltd. (MDWD) represents a high-potential biotechnology opportunity positioned to transform the global tissue repair and debridement markets.[1, 14] The company's approved biologic, NexoBrid, has established a high standard of care in severe burn treatment, supported by a 10-year BARDA procurement contract.[6, 10, 18] While the company's Q1 2026 top-line miss and delayed shipments caused near-term share price volatility, these issues have been resolved, and management reaffirmed its full-year 2026 guidance.[20, 28]
The core long-term investment catalyst is EscharEx, which targets a $2.0 billion+ chronic wound debridement market currently dominated by SANTYL.[13, 14] Clinical data show that EscharEx achieves complete debridement faster than standard care, which has facilitated strategic collaborations with major wound care companies.[7, 14, 22] Despite a delay in the Phase III VALUE trial's timeline, with completion now targeted for Q1 2027, the biological efficacy of the platform remains supported by clinical data.[14, 20]
The current valuation (Enterprise Value of approximately $135 million) is low relative to the company's projected 5-year sales growth CAGR of 58.2% and the market potential of its pipeline.[2, 31, 34, 38] Backed by strategic partners and recent insider buying, MediWound offers a favorable risk-reward profile for long-term investors.[7, 22, 41, 42]
CATALYST-RICH ASCENT
MediWound’s stock has consolidated in a sideways trading pattern, recently closing at $13.99 USD.[36, 37] The stock is currently trading below its 50-day Simple Moving Average (SMA) of $16.19 USD and its 200-day SMA of $17.36 USD, indicating a weaker technical setup following the Q1 2026 revenue miss.[20, 45] Critical near-term support is established in the $13.47 to $13.61 USD range, while key resistance is positioned at $14.89 USD.[36, 46] The short-term price outlook is expected to remain range-bound, sensitive to updates on EscharEx trial enrollment and the ramp-up of BARDA-related procurement revenues in the second half of 2026.[20, 36]
BEARISH CONSOLIDATION BREAKOUT
View MediWound Ltd. (MDWD) stock page
Loading the interactive version of this report…